Screener
Supernus Pharmaceuticals SUPN Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
| Diluted | $(0.04) | $(0.21) |
| Weighted average shares outstanding |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's net income?
- Supernus Pharmaceuticals (SUPN) reported net income of -$2.29M in Q1 2026.
- How has Supernus Pharmaceuticals's net income changed year-over-year?
- Supernus Pharmaceuticals's net income increased by 80.6% year-over-year, from -$11.83M to -$2.29M.
- What is the long-term trend for Supernus Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's net income has grown at a -7.8% compound annual growth rate (CAGR), from $53.42M to -$38.55M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Supernus Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude